Peripheral vascular disease and Virchow's triad for thrombogenesis

QJM: An International Journal of Medicine

Volumn 95, Issue 4, 2002, Pages 199-210

  Makin, A ^a   Silverman, S H ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; HOMOCYSTEINE; IBUPROFEN; PENTOXIFYLLINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ARTERY THROMBOSIS; BLOOD COMPONENT; BLOOD FLOW; BLOOD RHEOLOGY; BLOOD VESSEL WALL; BLOOD VISCOSITY; CONTROLLED STUDY; FIBRINOGEN BLOOD LEVEL; FLOW MEASUREMENT; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; PERIPHERAL VASCULAR DISEASE; PLASMA VISCOSITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOGENESIS; VEIN THROMBOSIS;

EID: 0036230928     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/95.4.199     Document Type: Review

References (96)

1. Intermittent claudication in 8343 men and 21-year specific mortality follow-up
2. Prevalence of intermittent claudication and its effect on mortality
3. Mortality over four years in SHEP participants with a low ankle-arm index
4. The demographics of claudication and the aging of the American population
5. Mortality over a period of 10 years in patients with peripheral arterial disease
6. Fate of the patient with chronic leg ischaemia: A review article
7. Critical and subcritical ischaemia
8. Cellular Pathology
9. Usefulness of waveform analysis of popliteal artery in type II diabetic patients using gated magnetic resonance 2D-cine-PC imaging and 31P spectroscopy
10. Hematocrit dependent changes of muscle tissue oxygen supply in the lower limb muscle of patients with intermittent claudication
11. Prevalence, risk factors and rheological profile of arterial vascular disease; first results of the Aachen study
12. Blood rheology associated with cardiovascular risk factors and chronic cardiovascular diseases: Results of an epidemiologic cross-sectional study
13. Haemostatic and rheological factors in intermittent claudication: The influence of smoking and extent of arterial disease
14. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study
15. Smoking, hemorheologic factors, and progression of peripheral arterial disease in patients with claudication
16. Plasma viscosity increase with progression of peripheral arterial atherosclerotic disease
17. Association of hypertension with blood viscosity in diabetes
18. Viscous factors in peripheral tissue perfusion
19. Von Willebrand factor, fibrinogen and other plasma proteins as determinants of plasma viscosity
20. Epidemiology of atherosclerotic peripheral arterial occlusive disease in Hong Kong
21. The role of haematological factors in diabetic peripheral arterial disease: The Edinburgh artery study
22. Changes in the fibrinolytic system in patients with peripheral arterial occlusive disease undergoing percutaneous transluminal angioplasty
23. Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease
24. Relation of haemostatic, fibrinolytic, and rheological variables to the angiographic extent of peripheral arterial occlusive disease
25. Fibrinogen and albuminuria are related to the presence and severity of peripheral arterial disease in women with type 2 diabetes mellitus
26. Haemostatic derangement in advanced peripheral occlusive arterial disease
27. Association of hemostatic factors with peripheral vascular disease
28. Plasma fibrinogen, haemostatic factors and prediction of peripheral arterial disease in the Edinburgh Artery Study
29. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants
30. Fibrinogen and mortality in chronic critical limb ischaemia
31. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants
32. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease: Results from the ADEP study
33. Effect of niacin supplementation on fibrinogen levels in patients with peripheral vascular disease
34. Fibrinogen and markers of fibrinolysis and endothelial damage following resolution of critical limb ischaemia
35. Effects of indobufen and pentoxifylline on walking capacity and hemostasis in patients with intermittent claudication: Results of six months of treatment
36. Association of increased fibrin turnover and defective fibrinolytic capacity with leg atherosclerosis The PLAT Group
37. Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease
38. Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty
39. Fibrin D-dimer, haemostatic factors and peripheral arterial disease
40. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin
41. Smoking, haemostatic factors and the severity of aorto-iliac and femoro-popliteal disease
42. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease
43. Haemostatic system activation and prediction of vascular events in patients presenting with stable peripheral arterial disease of moderate severity
44. Haemostatic and rheological factors as predictors of restenosis following percutaneous transluminal angioplasty
45. Influence of graft material on blood rheology and plasma biochemistry following insertion of an infrainguinal bypass graft
46. Activation of coagulation and fibrinolysis in patients with arteriosclerosis: Relation to localization of vessel disease and risk factors
47. Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease
48. Alteration of the fibrinolytic system in patients with peripheral arterial occlusive disease
49. Progressive intermittent claudication is associated with impaired fibrinolysis
50. Von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis
51. Acute exercise and markers of endothelial injury in peripheral arterial disease
52. Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, epiaortic and peripheral occlusive artery disease
53. Percutaneous angioplasty, endothelial markers, and fibrin turnover
54. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease
55. Circulating endothelial cell markers in peripheral vascular disease: Relationship to the location and extent of atherosclerotic disease
56. Relationship between endothelial cell markers and arterial stenosis in peripheral and carotid artery disease
57. Hyperhomocyst(e)inaemia: An independent risk factor for intermittent claudication
58. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease
59. Association between plasma homocysteine and peripheral arterial disease in older persons
60. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease
61. Homocysteine: An independent risk factor for the failure of vascular intervention
62. The progressive nature of peripheral arterial disease in young adults: A prospective analysis of white men referred to a vascular surgery service
63. Homocystine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis
64. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells
65. Hyperhomocysteinemia: An independent risk factor for vascular disease
66. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease
67. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease
68. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Homocysteine and peripheral vascular disease
69. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia
70. Endothelial reactivity and cardiac risk factors in older patients with peripheral arterial disease
71. Peripheral vascular endothelial dysfunction in patients with angina pectoris and normal coronary arteriograms
72. Circulating endothelial markers and ischemic status in peripheral occlusive arterial disease
73. In vivo femoropopliteal arterial wall compliance in subjects with and without lower limb vascular disease
74. Vascular abnormalities associated with long-term cigarette smoking identified by arterial waveform analysis
75. Radial artery compliance in patients with peripheral vascular disease
76. Aortic stiffening does not predict coronary and extracoronary atherosclerosis in asymptomatic men at risk for cardiovascular disease
77. Doppler ultrasound recognition of preclinical changes in arterial wall in diabetic subjects: Compliance and pulse-wave damping
78. Putative determinants of arterial wall compliance in NIDDM
79. Smokers exhibit an altered Doppler analog waveform during peripheral arterial examination
80. Decreased smooth muscle cell/extracellular matrix ratio of media of femoral artery in patients with atherosclerosis and hyperhomocysteinemia
81. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia
82. Large-artery elastic properties in young men: Relationships to serum lipoproteins and oxidized low-density lipoproteins
83. Evaluation of arterial compliance in patients with carotid arterial atherosclerosis
84. Variability in ultrasonic measurements of arterial stiffness in the Atherosclerosis Risk in Communities study
85. Does lowering of cholesterol levels influence functional properties of large arteries?
86. Flow patterns and spatial distribution of atherosclerotic lesions in human coronary arteries
87. In vivo association between low wall shear stress and plaque in subjects with asymmetrical carotid atherosclerosis
88. Carotid bifurcation atherosclerosis: Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress
89. Wall shear stress and early atherosclerotic lesions in the abdominal aorta in young adults
90. Atherosclerosis-prone branch regions in human aorta: Microarchitecture and cell composition of intima
91. Haematological stress syndrome in atherosclerosis
92. Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction
93. Von Willebrand factor as a marker of injury to the endothelium in inflammatory vascular disease
94. Vessel wall interactions regulating thrombosis
95. Warner-Lambert/Parke-Davis award lecture. Cytokine-mediated activation of vascular endothelium: Physiology and pathology
96. Femoral atherosclerosis in an older British population: Prevalence and risk factors